Amgen
Executive Summary
Company will acquire Medford, Mass.-based Kinetix for $170 mil. in stock. Privately held Kinetix specializes in discovering small molecule drugs in the field of protein kinase inhibition, and has oncological and anti-inflammatory agents in preclinical development. Kinetix CEO Nick Lydon, PhD, will relocate to Thousand Oaks, Ca., to become Amgen's VP-small molecule drug discovery, while Kinetix VP-R&D and Chief Scientific Officer David Armistead, PhD, will become VP-chemistry and will head Amgen's research programs in the Boston area. While remaining in their facilities at present, Kinetix' 40 employees may eventually move to Amgen's new research & drug discovery facility being built in Cambridge, Amgen said
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth